Remissions and progression of C3 glomerulopathy
- Authors: Karunnaya A.V.1, Dobronravov V.A.1
-
Affiliations:
- Pavlov First Saint Petersburg State Medical University
- Issue: Vol 94, No 6 (2022)
- Pages: 718-724
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/109607
- DOI: https://doi.org/10.26442/00403660.2022.06.201564
- ID: 109607
Cite item
Full Text
Abstract
Aim. To analyze the outcomes of C3-glomerulopathy (C3-GP) and determine the associated factors.
Materials and methods. A retrospective single-center study included 60 patients with newly diagnosed C3-GP (with primary C3-GP – pC3-GP – 82%). Of these, 48 (80%) patients had clinical data to assess the following disease outcomes: development of remission and disease progression (by a composite endpoint that included initiation of chronic dialysis or a decrease in estimated glomerular filtration rate – eGFR – <15 mL/min/1.73 m2 or a decrease in eGFR≥30% of baseline at the time of renal biopsy). The median follow-up period was 25 (7; 52) months.
Results. At early follow-up (median 4 [3; 9] months) remission was registered in 35% of patients; at the end of follow-up, in 48% (for pC3-GP, 32 and 41%). Disease progression occurred in 17 patients. In the overall group the likelihood of achieving early remission was higher with treatment (Expβ=6.4, 95% confidence interval – CI 1.4–29.3; p=0.017). Early remission was associated with the presence of remission at the end of follow-up (Expβ=6.3, 95% CI 2.2–18.4; p=0.001). Specific treatment (Expβ=0.308, 95% CI 0.108–0.881; p=0.028) and late remission (Expβ=0.079, 95% CI 0.017–0.368; p=0.001) were associated with reduced risk of disease progression in multivariable models (adjusted for eGFR, mean blood pressure). The same results were obtained for the group of patients with pC3-GP.
Conclusion. C3-GP is a variant of severe complement-mediated glomerular damage with unfavorable renal prognosis, which requires timely personalized expert-level diagnostics with clarification of etiopathogenesis of the disease followed by therapy aimed at achieving remission to improve outcomes.
Full Text
##article.viewOnOriginalSite##About the authors
Anna V. Karunnaya
Pavlov First Saint Petersburg State Medical University
Email: dobronravov@nephrolog.ru
ORCID iD: 0000-0003-0758-8137
врач-нефролог, зав. отд-нием хронического гемодиализа клиники Научно-исследовательского института нефрологии
Russian Federation, Saint PetersburgVladimir A. Dobronravov
Pavlov First Saint Petersburg State Medical University
Author for correspondence.
Email: dobronravov@nephrolog.ru
ORCID iD: 0000-0002-7179-5520
д-р мед. наук, проф., и.о. дир. клиники Научно-исследовательского института нефрологии, проф. каф. пропедевтики внутренних болезней с клиникой, проф. каф. нефрологии и диализа фак-та последипломного образования
Russian Federation, Saint PetersburgReferences
- Перечень редких (орфанных) заболеваний. Министерство здравоохранения Российской Федерации. Режим доступа: https://minzdrav.gov.ru/documents/8048/ Ссылка активна на 17.03.22 [List of rare (orphan) diseases. Ministry of Health of the Russian Federation. Available at: https://minzdrav.gov.ru/documents/8048/ Accessed: 17.03.2022 (in Russian)].
- Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079-89. doi: 10.1038/ki.2013.377
- Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539-51. doi: 10.1016/j.kint.2016.10.005
- Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci. 2020;21(2):525. doi: 10.3390/ijms2102052
- Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9(1):46-53. doi: 10.2215/CJN.04700513
- Bomback AS, Santoriello D, Avasare RS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018;93(4):977-85. doi: 10.1016/j.kint.2017.10.022
- Ravindran A, Fervenza FC, Smith RJH, et al. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. Mayo Clin Proc. 2018;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019
- Iatropoulos P, Daina E, Curreri M, et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol. 2018;29(1):283-94. doi: 10.1681/ASN.2017030258
- Nakagawa N, Mizuno M, Kato S, et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. PLoS One. 2021;16(9):e0257397. doi: 10.1371/journal.pone.0257397
- Rabasco C, Cavero T, Román E, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int. 2015;88(5):1153-60. doi: 10.1038/ki.2015.227
- Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, et al. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. Clin J Am Soc Nephrol. 2020;15(9):1287-98. doi: 10.2215/CJN.15241219
- Добронравов В.А., Карунная А.В. Этиология и клинико-морфологическая презентация С3-гломерулопатии (одноцентровое исследование 60 случаев). Нефрология. 2021;25(6):93-8 [Dobronravov VA, Karunnaya AV. Clinical and morphological presentation of C3 glomerulopathy: a single-center study of 60 cases. Nephrology (Saint-Petersburg). 2021;25(6):93-8 (in Russian)]. doi: 10.36485/1561-6274-2021-25-6-93-98
- Смирнов А.В., Афанасьев Б.В., Поддубная И.В., и др. Моноклональная гаммапатия ренального значения: консенсус гематологов и нефрологов России по введению нозологии, диагностике и обоснованности клон-ориентированной терапии. Нефрология. 2019;23(6):9-28 [Smirnov AV, Afanasyev BV, Poddubnaya IV, et al. Monoclonal gammopathy of renal signifi cance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment. Nephrology (Saint-Petersburg). 2019;23(6):9-28 (in Russian)]. doi: 10.36485/1561-6274-2019-236-9-28
- Caravaca-Fontán F, Díaz-Encarnación M, Cabello V, et al. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy. Nephrol Dial Transplant. 2021;gfab075. doi: 10.1093/ndt/gfab075
- Barbour TD, Pickering MC, Cook HT. Dense deposit disease and C3 glomerulopathy. Semin Nephrol. 2013;33(6):493-507. doi: 10.1016/j.semnephrol.2013.08.002
- Barbour TD, Ruseva MM, Pickering PM. Update on C3 glomerulopathy. Nephrol Dial Transplant. 2016;31(5):717-25. doi: 10.1093/ndt/gfu317
- De Vriese AS, Sethi S, Van Praet J, et al. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26(12):2917-29. doi: 10.1681/ASN.2015020184
- Chauvet S, Frémeaux-Bacchi V, Petitprez F, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017;129(11):1437-47. doi: 10.1182/blood-2016-08-737163
- Caravaca-Fontán F, Lucientes L, Serra N, et al. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. Nephrol Dial Transplant. 2021:gfab302. doi: 10.1093/ndt/gfab302
- Rudnicki M. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. Biomed Res Int. 2017;2017:2180508. doi: 10.1155/2017/2180508
- Avasare RS, Canetta PA, Bomback AS, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol. 2018;13(3):406-13. doi: 10.2215/CJN.09080817
- Zipfel PF, Wiech T, Rudnick R, et al. Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019;10:2166. doi: 10.3389/fimmu.2019.02166